Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas

Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination w...

Full description

Saved in:
Bibliographic Details
Published in:Neurology Vol. 67; no. 1; pp. 156 - 158
Main Authors: DOHERTY, L, GIGAS, D. C, KESARI, S, DRAPPATZ, J, KIM, R, ZIMMERMAN, J, OSTROWSKY, L, WEN, P. Y
Format: Journal Article
Language:English
Published: Hagerstown, MD Lippincott Williams & Wilkins 11-07-2006
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Biological and medical sciences
Brain Neoplasms - drug therapy
Brain Neoplasms - pathology
Chemotherapy
Drug Therapy, Combination
Enzyme Inhibitors - therapeutic use
Female
Glioma - drug therapy
Glioma - pathology
Humans
Male
Medical sciences
Middle Aged
Neurology
Pharmacology. Drug treatments
Pilot Projects
Protein Kinases - physiology
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Recurrence
Retrospective Studies
TOR Serine-Threonine Kinases
Tumors of the nervous system. Phacomatoses
Malignant glioma
Nervous system diseases
Malignant tumor
Recurrent
Central nervous system disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant gliomas are frequently characterized by amplification of the epidermal growth factor receptor (EGFR) and loss of PTEN tumor suppressor gene. Twenty-eight heavily pretreated patients with recurrent malignant gliomas were administered EGFR inhibitors (gefitinib or erlotinib) in combination with the mTOR (mammalian target of rapamycin) inhibitor sirolimus. The regimens were reasonably well tolerated. Nineteen percent of patients experienced a partial response and 50% had stable disease. Six-month progression-free survival for glioblastoma patients was 25%.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0028-3878
1526-632X
DOI:10.1212/01.wnl.0000223844.77636.29